Two decades of new drug discovery and development for Alzheimer's disease

被引:60
|
作者
Liu, Zhidong [1 ]
Zhang, Aihua [1 ]
Sun, Hui [1 ]
Han, Ying [1 ]
Kong, Ling [1 ]
Wang, Xijun [1 ,2 ]
机构
[1] Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem,Lab Metabol, Sino US Chinmed Technol Cooperat Ctr,Key Pharmaco, Chinmed Res Ctr TCM State Adm,Dept Pharmaceut Ana, Heping Rd, Harbin, Peoples R China
[2] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Ave Wai Long, Taipa, Macau, Peoples R China
来源
RSC ADVANCES | 2017年 / 7卷 / 10期
基金
黑龙江省自然科学基金;
关键词
M1 MUSCARINIC AGONISTS; GALANTAMINE PRO-DRUG; NERVE GROWTH-FACTOR; PHASE-II TRIAL; AMYLOID-BETA; A-BETA; OXIDATIVE STRESS; DOUBLE-BLIND; CHOLINERGIC HYPOTHESIS; EFFECTIVE CONSTITUENTS;
D O I
10.1039/c6ra26737h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Alzheimer's disease is a progressive and irreversible neurodegenerative disease, associated with a decreased cognitive function and severe behavioral abnormalities. Due to its complex pathophysiological characteristics, complicated interactions with a large number of genes and proteins, there is still no effective drug treatment of the disease. Amyloid cascade aggregation of senile plaques and hyperphosphorylation of Tau protein to form neurofibrillary tangles are the main pathological features of Alzheimer's disease, other mechanisms, such as oxidative stress, lack of central cholinergic neurotransmitters, inflammatory reaction and toxic metal ions have also been involved. The purpose of this review is to briefly introduce the progress of the development of the therapeutic agents based on their main mechanisms of action.
引用
收藏
页码:6046 / 6058
页数:13
相关论文
共 50 条
  • [1] Drug discovery and development for Alzheimer's disease
    Lyketsos, CG
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 10 (06): : 756 - 756
  • [3] Drug discovery and development for Alzheimer's disease, 2000
    Woodward, M
    INTERNATIONAL PSYCHOGERIATRICS, 2002, 14 (04) : 425 - 426
  • [4] Drug discovery, development and delivery in Alzheimer’s disease
    Davide Brambilla
    Pharmaceutical Research, 2018, 35
  • [5] New pathways in drug discovery for alzheimer’s disease
    Eric R. Siemers
    Robert A. Dean
    Ronald Demattos
    Patrick C. May
    Current Neurology and Neuroscience Reports, 2006, 6 : 372 - 378
  • [6] Alzheimer's disease: new approaches to drug discovery
    Bolognesi, Maria L.
    Matera, Riccardo
    Minarini, Anna
    Rosini, Michela
    Melchiorre, Carlo
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2009, 13 (03) : 303 - 308
  • [7] New pathways in drug discovery for Alzheimer's disease
    Siemers, Eric R.
    Dean, Robert A.
    Demattos, Ronald
    May, Patrick C.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2006, 6 (05) : 372 - 378
  • [8] New Drug Development in Alzheimer's Disease
    Apter, Jeffrey
    Liebowitz, Michael
    NEUROPSYCHOPHARMACOLOGY, 2023, 48 : 296 - 296
  • [9] The challenges of drug discovery and drug development for cognitive aging and Alzheimer's disease
    Fillit, H
    O'Connell, A
    DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE, 2000, 2002, : 1 - 4
  • [10] Increasing the success rate for Alzheimer's disease drug discovery and development
    Becker, Robert E.
    Greig, Nigel H.
    EXPERT OPINION ON DRUG DISCOVERY, 2012, 7 (04) : 367 - 370